Toyama, Japan

Junichi Mitsuyama

This inventor holds 5 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents. Top assignee: Toyama Chemical Co., Ltd.. Active years: 1994-2012.


% Patents Active = 80.0


 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 20(Granted Patents)


Location History:

  • Kamiichi-machi, JP (2007)
  • Toyama, JP (1994 - 2012)

Company Filing History:


Years Active: 1994-2012

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Junichi Mitsuyama: Innovator in Antifungal Agents

Introduction

Junichi Mitsuyama is a prominent inventor based in Toyama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antifungal agents. With a total of 5 patents, Mitsuyama's work is recognized for its innovative approaches to drug formulation.

Latest Patents

Mitsuyama's latest patents include a novel crystal form of 4-{3-[4-(3-{4-[amino(butoxycarbonylimino)methyl]phenoxy}propyl)-1-piperidinyl]propoxy}-N'-(butoxycarbonyl)benzamidine. This invention aims to provide excellent drug substances that serve as antifungal agents. Additionally, he has developed an arylamidine derivative that exhibits remarkable antifungal action and high safety, making it a valuable asset in pharmacotherapy.

Career Highlights

Mitsuyama is currently associated with Toyama Chemical Co., Ltd., where he continues to push the boundaries of pharmaceutical innovation. His work has not only advanced the understanding of antifungal agents but has also contributed to the overall improvement of drug safety and efficacy.

Collaborations

Mitsuyama collaborates with notable colleagues such as Kazuya Hayashi and Hiroyuki Imaizumi. Their combined expertise enhances the research and development efforts at Toyama Chemical Co., Ltd.

Conclusion

Junichi Mitsuyama's contributions to the field of antifungal agents highlight his role as a key innovator in pharmaceuticals. His patents reflect a commitment to improving drug formulations and patient safety.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…